Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:

• Citi 18th Annual BioPharma Conference, Boston, MASeptember 6, 2023
• Wells Fargo Healthcare Conference, Boston, MASeptember 7, 2023, 8:00 am EDT
• Morgan Stanley 21st Annual Global Healthcare Conference, New York, NYSeptember 11, 2023
• Jefferies Cell & Genetic Medicine Summit, New York, NYSeptember 26-27, 2023

For more information and links to available webcasts, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the events.

About Caribou’s novel next-generation CRISPR platformCRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:Investors:Amy Figueroa, CFA[email protected]

Media:Peggy Vorwald, PhD[email protected]

Source: Caribou Biosciences, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• San Joaquin Valley College Hosts Skilled Trades Night
• SEMI and Silicon Catalyst Aim to Accelerate Global Semiconductor Innovation with Strategic Partnership
• Beyond the Remedy: An Expert Conversation on Complex Remediation Projects